SEC Form 4 · accession 0001661181-18-000035
Organogenesis Holdings Inc. · ORGO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick Bilbo
Officer — Chief Operating Officer
Period of report
Dec 10, 2018
Accepted (ET)
Dec 12, 2018 · 7:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001661181
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 10, 2018 | A | 121,800 | — | A | 121,800 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3,F2 | $1.44 | Dec 10, 2018 | A | 30,450 | A | — | Dec 6, 2021 | Common Stock | 30,450 | 30,450 | D |
| Stock Option (Right to Buy)F5,F4 | $1.18 | Dec 10, 2018 | A | 152,250 | A | — | Apr 10, 2024 | Common Stock | 152,250 | 152,250 | D |
| Stock Option (Right to Buy)F7,F6 | $3.46 | Dec 10, 2018 | A | 142,100 | A | — | May 4, 2027 | Common Stock | 142,100 | 142,100 | D |
| Stock Option (Right to Buy)F9,F8 | $3.46 | Dec 10, 2018 | A | 101,500 | A | — | May 4, 2027 | Common Stock | 101,500 | 101,500 | D |
Explanation of responses
- F1Received in connection with the Issuer's business combination (the "Merger") with Organogenesis Inc. ("Organogenesis") in accordance with the terms of the Agreement and Plan of Merger dated as of August 17, 2018 among the Issuer, which was then referred to as Avista Healthcare Public Acquisition Corp., Avista Healthcare Merger Sub, Inc. and Organogenesis, in exchange for 60,000 shares of common stock of Organogenesis.
- F2100% of the shares subject to this option are fully vested and exercisable.
- F3Received in connection with the Merger in exchange for an option to acquire 15,000 shares of common stock of Organogenesis for $2.92 per share.
- F4The shares underlying the option vested or shall vest 20% annually beginning on January 1, 2015.
- F5Received in connection with the Merger in exchange for an option to acquire 75,000 shares of common stock of Organogenesis for $2.38 per share.
- F6The shares underlying the option vested or shall vest 20% annually beginning on December 31, 2017.
- F7Received in connection with the Merger in exchange for an option to acquire 70,000 shares of common stock of Organogenesis for $7.01 per share.
- F8The shares underlying the option vested or shall vest 20% annually beginning on January 1, 2018.
- F9Received in connection with the Merger in exchange for an option to acquire 50,000 shares of common stock of Organogenesis for $7.01 per share.